Address: Medialaan 38, 1800, Vilvoorde, Belgium
Tel: +32 2 627 3211
Web: http://www.imshealth.com/portal/site/ims
IMS HEALTH, operating in more than 100 countries, is one of the world’s leading providers of market intelligence to the pharmaceutical and healthcare industries. With more than 55 years of industry experience, IMS Health offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide.
Healthcare Measurement: Indispensable patient, provider and payer insights, and market-defining methodologies.
Healthcare Analytics & Services: Integrated solutions across healthcare to optimize commercial effectiveness, clinical decisions and care delivery.
Consulting: Specialized expertise for enabling and accelerating informed decisions in life sciences.
Kalin Tochev, country manager of IQVIA Bulgaria, discusses the main trends taking place in the Bulgarian pharmaceutical sector and highlights the end-to-end approach that IQVIA offers to its clients to…
Jack Daly, Commercial Manager at IMS Health Ireland, discusses the strategic decision of IMS Health to diversify into the health consultancy space, the importance of developing long-term partnerships with clients…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much…
Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last…
In part II of an exclusive interview at the eyeforpharma Barcelona Summit 2016, IMS Health’s Chief Digital Officer Richie Etwaru lifts the lid on the concept of Orchestrated Customer Engagement (OCE) and…
A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through…
IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The general manager of IMS Health Argentina – South Cone weighs in on why his organization plays a crucial role in the pharma industry in Argentina. How does the Argentinean…
The general manager of the leading information solutions provider for the pharmaceutical and healthcare industry talks about the challenges Mexican patients face in the public sector, how large pharmacy chains…
IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also…
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
Al Z. Castro, General Manager of IMS Health Philippines, speaks about the ongoing challenges of bringing about awareness and acceptance of generics medicine to the local population, how this will…
Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How…
Alex Ho has more than 15 years of significant pharmaceutical industry expertise, spanning across sales, marketing and product management in multinational companies. These companies include Novartis, Janssen, L’Oreal, GSK and…
Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time as a post-doctoral researcher…
What attracted you to IMS Health? I was most attracted by the fact that IMS is able to actually change healthcare systems. I think IMS is a very important player…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a…
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
IMS was recently acquired by two investment funds, how has this affected the operations of the company and what changes did it bring in the Chilean context? So far, the…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS operations? IMS has been…
Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
IMS ‘lives and breathes the pharma industry’ and it is stimulating to come from other forms of consultancy to IMS. You have worked in various businesses. What motivated you to…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to…
You worked as a Country Manager in Indonesia and Thailand prior to joining IMS Health in the Philippines. What, in your opinion, sets this market apart? For starters, Indonesia is…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
See our Cookie Privacy Policy Here
